Full Text of PDF (478k)
Article in Japanese
Abstract
Case Report
A case of positive for ALK rearrangement lung adenocarcinoma recurred during administration of alectinib, improving after switching to ceritinib
Kazuyoshi Watanabea Yuko Wasedaa Hazuki Takatoa Hiroki Matsuokaa Kazuo Kasaharab
aDepartment of Respiratory Medicine, Japan Community Health Care Organization Kanazawa Hospital
bDepartment of Respiratory Medicine, Kanazawa University Hospital
ABSTRACT
A 61-year-old man was diagnosed positive for anaplastic lymphoma kinase (ALK) rearrangement lung cancer (cT4N2M1a Stage IV) and given platinum combination chemotherapy. Improvement was noted, but tumors subsequently increased. Crizotinib was started, and primary tumors of the lung were reduced, but neutropenia was gradually appeared and worsened. Crizotinib was stopped. The tumors increased, and alectinib was started, but it was ineffective. Alectinib was changed to ceritinib, and a chest CT examination showed remarkable improvement. This case suggests that ceritinib is effective in some patients with ALK-positive adenocarcinoma previously treated with alectinib.
KEYWORDS
Crizotinib Alectinib Ceritinib Positive for ALK rearrangement lung adenocarcinoma
Received 10 Feb 2017 ／ Accepted 25 Apr 2017
AJRS, 6(4): 278-282, 2017
Copyright © The Japanese Respiratory Society All Rights Reserved.